|Assembly Actions - Lowercase
Senate Actions - UPPERCASE
|Mar 03, 2017||referred to health|
senate Bill S4986
Archive: Last Bill Status - In Senate Committee Health Committee
- In Committee
- On Floor Calendar
- Passed Senate
- Passed Assembly
- Delivered to Governor
- Signed/Vetoed by Governor
S4986 (ACTIVE) - Details
S4986 (ACTIVE) - Summary
Enacts the pharmaceutical cost transparency act requiring prescription drug manufacturers to file a report disclosing certain financial information pertaining to prescription drugs which have a wholesale acquisition cost of $10,000 or more annually or per course of treatment.
S4986 (ACTIVE) - Sponsor Memo
BILL NUMBER: S4986 TITLE OF BILL : An act to amend the public health law, in relation to establishing the pharmaceutical cost transparency act of 2017 PURPOSE : To make information available to the public about the cost of ultra-high-priced pharmaceuticals SUMMARY OF PROVISIONS : Section 1. Establishes the pharmaceutical transparency act of 2017. Section 2 Amends the public health law by adding a new section, 278-a. Legislative intent, including annual cost reporting on the most expensive drugs Provides that each manufacturer of a prescription drug that is made available in New York State, that has a wholesale acquisition cost of ten thousand dollars shall file an annual report with the department no later than May 1 of each year on a form prescribed by the department. Specifies the content of such report, including but not limited to the total cost for the production of each drug; the total research and development costs for each drug; and the total costs of clinical trials and other regulatory costs for each drug. Requires that all of the information in the report shall be itemized by manufacturer and audited by a fully independent third
S4986 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 4986 2017-2018 Regular Sessions I N S E N A T E March 3, 2017 ___________ Introduced by Sen. DIAZ -- read twice and ordered printed, and when printed to be committed to the Committee on Health AN ACT to amend the public health law, in relation to establishing the pharmaceutical cost transparency act of 2017 THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. This act shall be cited and may be known as the "pharmaceu- tical cost transparency act of 2017". § 2. The public health law is amended by adding a new section 278-a to read as follows: § 278-A. PRESCRIPTION DRUG COST TRANSPARENCY. 1. LEGISLATIVE INTENT. A. IT IS THE INTENT OF THE LEGISLATURE TO MAKE INFORMATION AVAILABLE TO THE PUBLIC ABOUT THE COST OF ULTRA-HIGH-PRICED PHARMACEUTICALS, IN ORDER TO MAKE PHARMACEUTICAL PRICING AS TRANSPARENT AS THE PRICING IN OTHER SECTORS OF THE HEALTH CARE INDUSTRY. B. THE LEGISLATURE FINDS THAT THERE SHOULD BE ANNUAL COST REPORTING ON THE MOST EXPENSIVE DRUGS THAT WOULD BE OF USE TO POLICYMAKERS, GOVERN- MENT AGENCIES, AND OTHERS TO UNDERSTAND COSTS FOR THESE IMPORTANT PRODUCTS. 2. EACH MANUFACTURER OF A PRESCRIPTION DRUG, MADE AVAILABLE IN NEW YORK, THAT HAS A WHOLESALE ACQUISITION COST OF TEN THOUSAND DOLLARS ($10,000) OR MORE ANNUALLY OR PER COURSE OF TREATMENT, SHALL FILE A REPORT PURSUANT TO THIS SECTION ON THE COSTS FOR EACH QUALIFYING DRUG. 3. THE REPORT REQUIRED PURSUANT TO SUBDIVISION TWO OF THIS SECTION SHALL INCLUDE ALL OF THE FOLLOWING FOR EACH DRUG: A. THE TOTAL COSTS FOR THE PRODUCTION OF THE DRUG, INCLUDING ALL OF THE FOLLOWING: (I) THE TOTAL RESEARCH AND DEVELOPMENT COSTS PAID BY THE MANUFACTURER, AND SEPARATELY, THE TOTAL RESEARCH AND DEVELOPMENT COSTS PAID BY ANY PREDECESSOR IN THE DEVELOPMENT OF THE DRUG. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD07382-01-7
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.